Compound 1 does not increase the binding of β 3 LIBS antibodies and only partially increases the binding of an α IIb LIBS antibody to washed platelets
| mAb . | Target . | mAb binding, % value with tirofiban . | |
|---|---|---|---|
| Untreated platelets . | Compound 1 . | ||
| PMI-1 | αIIb | 11 ± 4.1 | 44 ± 8.7* |
| LIBS-1 | β3 | 9.0 ± 3.1 | 5.7 ± 6.3 |
| AP5 | β3 | 19 ± 6.2 | 26 ± 5.9 |
| mAb . | Target . | mAb binding, % value with tirofiban . | |
|---|---|---|---|
| Untreated platelets . | Compound 1 . | ||
| PMI-1 | αIIb | 11 ± 4.1 | 44 ± 8.7* |
| LIBS-1 | β3 | 9.0 ± 3.1 | 5.7 ± 6.3 |
| AP5 | β3 | 19 ± 6.2 | 26 ± 5.9 |
Washed platelets were treated with compound 1 (100 μM), DMSO (1%), or tirofiban (100 μM) for 15 minutes at 37°C before labeling with mAbs for 30 minutes at 22°C in the dark. Samples were diluted 1:10 and analyzed by flow cytometry. Binding was calculated as the percentage of binding to platelets treated with 100 μM tirofiban. Data are presented as mean plus or minus SD values (n = 5).
P < .001 versus PMI-1 binding to untreated platelets.